Waldencast PLC (WALD) FinancialsWALDWaldencast PLC

Waldencast PLC (WALD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical, accounting for 72.6% of total sales, equivalent to $44.10M. Other significant revenue streams include Clinical and Other. Understanding this composition is critical for investors evaluating how WALD navigates market cycles within the Miscellaneous Specialty Retailers industry.

Evaluating the bottom line, Waldencast PLC maintains a gross margin of 53.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -139.58%, while the net margin is -362.88%. These profitability ratios, combined with a Return on Equity (ROE) of -33.47%, provide a clear picture of how effectively WALD converts its operational activities into shareholder value.

In the context of the broader market, WALD competes directly with industry leaders such as SLSN and GROV. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, WALD's gross margin of 53.67% stands against SLSN's 30.97% and GROV's 55.82%. Such benchmarking helps identify whether Waldencast PLC is trading at a premium or discount relative to its financial performance.

Waldencast reported a Q4 net loss of $33.5 million and has seen a significant decline in revenue, with a year-over-year decline of 0.1% in Q4 2025. The gross margin is relatively strong at 72.13% for Q1 2025, but overall financial health is concerning due to ongoing losses.